230 related articles for article (PubMed ID: 33618009)
21. Compensated Interferometry Measures of CYFRA 21-1 Improve Diagnosis of Lung Cancer.
Kammer MN; Kussrow AK; Webster RL; Chen H; Hoeksema M; Christenson R; Massion PP; Bornhop DJ
ACS Comb Sci; 2019 Jun; 21(6):465-472. PubMed ID: 31022347
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
[TBL] [Abstract][Full Text] [Related]
23. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
25. Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
Lastwika KJ; Kargl J; Zhang Y; Zhu X; Lo E; Shelley D; Ladd JJ; Wu W; Kinahan P; Pipavath SNJ; Randolph TW; Shipley M; Lampe PD; Houghton AM
Am J Respir Crit Care Med; 2019 May; 199(10):1257-1266. PubMed ID: 30422669
[No Abstract] [Full Text] [Related]
26. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
[TBL] [Abstract][Full Text] [Related]
27. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
[TBL] [Abstract][Full Text] [Related]
28. [Value of Combined Detection of Cytokines and Tumor Markers in the
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
[TBL] [Abstract][Full Text] [Related]
29. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease.
Chen F; Li J; Qi X; Qi J
J Cancer Res Ther; 2018 Jun; 14(Supplement):S400-S404. PubMed ID: 29970696
[TBL] [Abstract][Full Text] [Related]
31. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
32. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic value of serum tumor markers in differentiating malignant from benign solitary pulmonary nodules].
Ni LF; Liu XM
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):707-10. PubMed ID: 25331391
[TBL] [Abstract][Full Text] [Related]
34. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions].
Yang JG; Li CL; Gong M; Zou LF
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
36. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
[TBL] [Abstract][Full Text] [Related]
37. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
38. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
[TBL] [Abstract][Full Text] [Related]
39. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
[TBL] [Abstract][Full Text] [Related]
40. Correlations of pathological stage and prognosis of NSCLC patients with changes in serum CEA and CYFRA 21-1 and CT characteristics.
Zhao W; Liu Y; Kong F; Li Y
Panminerva Med; 2020 Mar; 62(1):67-69. PubMed ID: 31144789
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
